Recap: BioCryst Pharmaceuticals Q1 Earnings

BioCryst Pharmaceuticals BCRX reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM.

Here's what investors need to know about the announcement.

BioCryst Pharmaceuticals missed estimated earnings by 8.11%, reporting an EPS of $-0.4 versus an estimate of $-0.37.

Revenue was up $30.86 million from the same period last year.

Last quarter the company missed on EPS by $0.1 which was followed by a 0.12% drop in the share price the next day.

Here's a look at BioCryst Pharmaceuticals's past performance:

Quarter	Q4 2021	Q3 2021	Q2 2021	Q1 2021
EPS Estimate	-0.3	-0.29	-0.24	-0.27
EPS Actual	-0.4	-0.33	-0.24	-0.36
Revenue Estimate	50.56M	39.38M	28.48M	8.89M
Revenue Actual	47.16M	40.99M	49.96M	19.06M

To track all earnings releases for BioCryst Pharmaceuticals visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Calendar